Scarica l'app Stockscreener
0.955
2.55%
-0.025
Pre-mercato:
.95
-0.005
-0.52%
Mira Pharmaceuticals Inc Borsa (MIRA) Ultime notizie
MIRA Pharmaceuticals begins Phase 1 trial for pain treatment By Investing.com - Investing.com Australia
MIRA Pharmaceuticals begins Phase 1 trial for pain treatment - Investing.com India
MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain - ACCESS Newswire
Game-Changing Pain Treatment Enters Clinical Trials: Superior to Current Options in Early Data - Stock Titan
Mira Pharmaceuticals IncEnrolls First Subjects In Phase 1 Trial For Ketamir-2SEC Filing - MarketScreener
63,410 Shares in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Purchased by Virtu Financial LLC - Defense World
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Up 38.9% in March - Defense World
MIRA Pharmaceuticals (MIRA) Expected to Announce Earnings on Monday - Defense World
MIRA Pharmaceuticals Inc. (MIRA) reports earnings - Quartz
MIRA Pharmaceuticals (NASDAQ:MIRA) Stock Price Down 4.3% – Here’s What Happened - Defense World
MIRA bids for SKNY - The Pharma Letter
MIRA Pharmaceuticals to acquire SKNY for obesity, smoking therapy By Investing.com - Investing.com South Africa
MIRA Pharmaceuticals signs LOI to acquire SKNY Pharmaceuticals - MSN
MIRA Pharmaceuticals to acquire SKNY for obesity, smoking therapy - Investing.com
MIRA Pharmaceuticals to Acquire SKNY in Stock Deal By Investing.com - Investing.com South Africa
MIRA Pharmaceuticals to Acquire SKNY in Stock Deal - Investing.com India
Mira Pharmaceuticals Inc To Acquire Skny PharmaceuticalsSEC Filing -March 24, 2025 at 08:02 am EDT - MarketScreener
EXCLUSIVE: Anixa Biosciences Poised To Receive US Patent For Ovarian Cancer Vaccine - Benzinga
MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development - ACCESS Newswire
Major Pharma Deal: MIRA's $5M Backed Entry Into $150B Weight Loss Market - Stock Titan
EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug - Yahoo Finance
NRx Pharmaceuticals submits NDA for intravenous ketamine drug - Mugglehead
Mira Pharmaceuticals expands pain management pipeline By Investing.com - Investing.com Australia
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial - Yahoo Finance
Mira Pharmaceuticals Develops Topical Formulation of Ketamir-2 for Pain Relief -March 13, 2025 at 09:30 am EDT - Marketscreener.com
Mira Pharmaceuticals succesfully develops topical version of its therapy for localized neuropathic and inflammatory pain - Marketscreener.com
Mira Pharmaceuticals expands pain management pipeline - Investing.com India
Mira Pharmaceuticals expands Ketamir-2 development with topical treatment - TipRanks
MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain - Weatherford Democrat
Revolutionary Topical Pain Treatment: MIRA's Ketamir-2 Targets Multiple Pain Conditions - StockTitan
EXCLUSIVE: MIRA Pharmaceuticals Expands Pipeline, Enhances Value Proposition With Development Of Topical Formulation For Lead Pain Treatment Candidate - Benzinga
What is Zacks Small Cap’s Estimate for MIRA FY2024 Earnings? - Armenian Reporter
What is Zacks Small Cap’s Forecast for MIRA FY2024 Earnings? - Defense World
Mira Pharmaceuticals begins phase 1 trial for pain treatment By Investing.com - Investing.com Australia
SponsoredImpartialComprehensive - Research Tree
Urgent Boots paracetamol recall after packets found to contain a different drug - AOL
Mira Pharmaceuticals Announces Approval And Initiation Of Phase 1 Clinical Trial For Ketamir-2 In Neuropathic Pain - Marketscreener.com
Mira Pharmaceuticals begins phase 1 trial for pain treatment - Investing.com
Mira Pharmaceuticals announces approval, initiation of Phase 1 Ketamir-2 trial - TipRanks
MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain - accessnewswire.com
Can This Novel Ketamine Analog Outperform Gabapentin? MIRA's Neuropathic Pain Drug Enters Clinical Trials - StockTitan
EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain - Benzinga India
Tiziana stock jumps 12% on TBI drug study publication - MSN
A little-known Chinese company made a drug that beat the world’s biggest-selling medicine - AOL
Mira Murati's new AI startup poaches 20 OpenAI researchers - Reuters
MediPharm Labs terminates proposed sale of Napanee facility to Kensana Health - Seeking Alpha
Microstrategy Inc. – 8% PRF PERPETUAL USD 100 – Ser A’s (STRK) Stock: A Week-by-Week Analysis - The News Heater
Monday.Com Ltd (MNDY) Shares Down Despite Recent Market Volatility - The News Heater
Mira Pharmaceuticals Inc (MIRA) Stock: Evaluating the Market Performance - The News Heater
Vanda Pharmaceuticals Inc (VNDA) Shares Rise Despite Market Challenges - The News Heater
Air Transport Services Group Inc (ATSG) Stock: Evaluating the Market Performance - The News Heater
Report: OpenAI's ex-CTO, Mira Murati, has recruited OpenAI co-founder John Schulman - Yahoo Finance
OpenAI cofounder John Schulman is joining Mira Murati’s startup after brief stint at Anthropic - Yahoo Finance
2.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):